Narcolepsy — Causes, Symptoms, Cataplexy, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Narcolepsy is a chronic neurological disorder of sleep-wake state control, characterised by the pentad of: excessive daytime sleepiness (EDS — the cardinal symptom, present in virtually all cases); cataplexy (sudden bilateral loss of muscle tone triggered by emotions, particularly laughter — pathognomonic of Type 1 narcolepsy); hypnagogic or hypnopompic hallucinations (vivid, often frightening hallucinations at sleep onset or awakening); sleep paralysis (transient inability to move at sleep onset or awakening while conscious); and disrupted nocturnal sleep. Narcolepsy Type 1 (NT1) is caused by selective loss of approximately 70,000-90,000 hypothalamic neurons producing orexin (also called hypocretin) — a neuropeptide essential for maintaining wakefulness and inhibiting REM sleep. NT1 is characterised by cataplexy, low or absent cerebrospinal fluid (CSF) orexin-A levels (below 110 pg/mL), and positive HLA-DQB1*06:02 genetic marker (present in 85-95% of NT1 patients). Narcolepsy Type 2 (NT2) has normal CSF orexin levels, lacks cataplexy, and has a less well-understood pathogenesis. Narcolepsy affects approximately 1 in 2,000 individuals globally. Despite being a recognised and diagnosable neurological disorder, average diagnostic delay from symptom onset to diagnosis is 8-10 years — often misdiagnosed as depression, epilepsy, or behavioural problems in children.

Narcolepsy Type 1 is caused by autoimmune destruction of orexin-producing neurons in the lateral hypothalamus. The evidence for an autoimmune mechanism is compelling: extremely strong HLA association (HLA-DQB1*06:02 present in 85-95% of NT1 patients versus 25% of the general population; HLA class II molecules present antigens to CD4+ T cells); association with specific T-cell receptor alpha chain variants; and the Pandemrix (H1N1 influenza vaccine) link — a marked increase in NT1 incidence was documented in Northern Europe (particularly Scandinavia and the UK) in children aged 5-19 following Pandemrix vaccination in 2009-2010, likely from molecular mimicry between the influenza nucleoprotein and an orexin peptide sequence. Natural H1N1 influenza infection also appears to precipitate NT1. Orexin (hypocretin) normally stabilises wake-promoting circuits and inhibits REM sleep generating circuits in the brainstem (particularly the sublaterodorsal nucleus). Orexin deficiency causes inappropriately timed REM sleep intrusions during wakefulness — which accounts for cataplexy (REM atonia during waking), sleep paralysis (persistent REM atonia on waking), hypnagogic hallucinations (REM dreaming during transitional sleep), and the fundamental inability to maintain sustained wakefulness.

Excessive daytime sleepiness (EDS): the defining symptom — irresistible urge to sleep at inappropriate times and places (meetings, mid-conversation, meals, driving — dangerous); sleep attacks (sudden, brief episodes of sleep lasting seconds to minutes); refreshing brief naps (a distinguishing feature from other causes of EDS — narcoleptic patients feel alert for 30-60 minutes after a brief nap, unlike those with obstructive sleep apnoea or idiopathic hypersomnia). EDS profoundly impairs work performance, academic achievement, driving safety, and social function. Cataplexy (NT1 only): sudden loss of bilateral muscle tone — typically triggered by positive emotions (laughter, excitement, surprise, pride) much more than negative emotions; ranges from subtle (slurring of speech, jaw dropping, head nodding, knee buckling) to complete bilateral muscle paralysis causing falls; consciousness is preserved throughout; episodes last seconds to 2 minutes; extremely pathognomonic for NT1 — rarely caused by any other condition. Sleep paralysis: transient (seconds to minutes) inability to move or speak when waking up or falling asleep, while fully conscious; often frightening; approximately 40-50% of narcoleptics experience it regularly. Hypnagogic (at sleep onset) or hypnopompic (on waking) hallucinations: vivid, dream-like, multimodal hallucinations; frequently frightening (threat-related content — intruders, monsters); may be visual, auditory, or tactile; occur at sleep-wake transitions. Disrupted nocturnal sleep: paradoxically, narcoleptic patients frequently have fragmented nocturnal sleep — frequent arousals and REM sleep redistribution throughout the night.

Diagnosis of narcolepsy requires a thorough sleep evaluation in a specialist sleep centre. Overnight polysomnography (PSG): performed first to exclude other causes of daytime sleepiness (particularly obstructive sleep apnoea — the most common cause of EDS — which must be treated before MSLT interpretation); in narcolepsy, PSG typically shows sleep-onset REM periods (SOREMP — REM sleep occurring within 15 minutes of sleep onset, normally requiring approximately 80-90 minutes); reduced REM sleep latency and increased nocturnal REM density. Multiple Sleep Latency Test (MSLT — the gold standard diagnostic test): performed the day after overnight PSG; patient given 5 standardised 20-minute nap opportunities every 2 hours; in narcolepsy: mean sleep latency at or below 8 minutes (indicates pathological sleepiness; healthy adults: 10-20 minutes) AND 2 or more sleep-onset REM periods (SOREMPs) across the 5 naps. CSF orexin-A measurement (hypocretin-1 level): gold standard for NT1 diagnosis — obtained by lumbar puncture; level at or below 110 pg/mL (or less than one third of mean control values) is diagnostic of NT1, even without MSLT; highly sensitive and specific. HLA-DQB1*06:02 typing: positive in 85-95% of NT1; its absence argues strongly against NT1; however, it is present in 25% of the general population and cannot alone diagnose narcolepsy. Differentials to exclude: idiopathic hypersomnia (EDS without cataplexy, normal or borderline MSLT, normal CSF orexin); obstructive sleep apnoea; periodic limb movement disorder; depression; circadian rhythm disorders; medication-related EDS; and (rarely) epilepsy for cataplexy-like events.

There is no cure for narcolepsy — treatment is symptomatic and lifelong. Excessive daytime sleepiness: Modafinil (100-400 mg morning, or split morning and noon) is the first-line wake-promoting medication — a non-amphetamine wake-promoting agent with a favourable side effect profile; armodafinil (the R-enantiomer — 75-250 mg) has a slightly longer half-life. Pitolisant (Wakix — histamine H3 receptor inverse agonist): first non-scheduled treatment for EDS in narcolepsy; approved in EU and USA; can be used in combination with modafinil; requires no special scheduling (not a controlled substance — advantageous for those with occupational restrictions or substance use history). Solriamfetol (Sunosi — dopamine and norepinephrine reuptake inhibitor): approved for NT1 and NT2 EDS — effective once-daily dosing. Amphetamines and methylphenidate: historically first-line, still used when other agents are inadequate; higher dependence potential, more restricted prescribing. Cataplexy management: Sodium oxybate (Xyrem — the gamma-hydroxybutyrate salt) is the most effective treatment for cataplexy and also significantly improves EDS and nocturnal sleep quality; taken twice nightly (at bedtime and 2.5-4 hours later); FDA and EMA-approved for both NT1 and NT2; requires careful titration (2.25-4.5 g per dose) and restricted prescribing due to misuse potential. Low-sodium oxybate (Lumryz — extended-release once-nightly formulation) recently approved. Venlafaxine (SNRI — 37.5-225 mg) and clomipramine (TCA): anticataplectic through noradrenergic effects — widely used where sodium oxybate is unavailable or refused. Fluoxetine (SSRI): mild anticataplectic effect. Scheduled naps: 2-3 brief (15-20 minute) scheduled naps during the day significantly reduce EDS and can reduce medication requirements — a highly practical, cost-free adjunct. Lifestyle modifications: strict sleep schedule; avoiding shift work and sleep deprivation; avoiding alcohol (worsens REM dysregulation); driving restrictions (many countries require medical assessment for fitness to drive — patients must be adequately treated and have discussed with their physician).

Sleep-related accidents (untreated narcolepsy carries a 2-4 fold increased motor vehicle accident risk — sleep attacks can occur without warning while driving; patients must notify the DVLA in the UK or equivalent licensing authority, and must not drive until EDS is adequately controlled). Academic and occupational impairment (the mean 8-10 year diagnostic delay results in years of unexplained poor school performance, job loss, and career disruption — substantial, preventable psychosocial harm). Comorbid psychiatric conditions (depression and anxiety affect 30-50% of narcolepsy patients — both as a reaction to chronic disability and as a potential neurological consequence of orexin system dysfunction; requiring concurrent treatment). Weight gain and metabolic complications (orexin deficiency impairs satiety signalling — BMI is significantly elevated in narcolepsy patients, worsening functional status and sleep quality). Cataplexy-related physical injury (falls from severe cataplectic attacks — particularly head trauma — may require supervised daily activities during treatment initiation).

Narcolepsy cannot currently be prevented — once orexin neurons are destroyed, they do not regenerate. Management focuses on safety and quality of life optimisation. Driving safety: all patients with narcolepsy must notify their driving licensing authority and discuss fitness to drive with their physician — most regulatory bodies allow driving once narcolepsy is well-controlled on treatment; driving should be avoided immediately after diagnosis until EDS is adequately treated and stable. Occupational implications: narcolepsy qualifies as a disability under equality legislation in many countries (UK Equality Act 2010, ADA in USA) — reasonable workplace adjustments (scheduled rest breaks, shift work avoidance) should be requested from employers. Sleep hygiene and scheduling: consistent sleep and wake times; brief (20-minute) strategic naps; avoiding alcohol and sedating medications; exercising regularly. Patient support organisations (Narcolepsy Network USA, Narcolepsy UK) provide peer support, education, and advocacy — connecting patients with the narcolepsy community significantly improves psychological wellbeing. School and paediatric management: children with narcolepsy require school accommodations (extra time in examinations, permission to nap, reduced schedule if needed). Emerging treatments in clinical trials: orexin receptor agonists (TAK-994 — oral orexin-2 receptor agonist — showed remarkable efficacy in Phase II trials; development temporarily paused due to liver toxicity signal; next-generation compounds in development); and immune-based therapy to prevent NT1 in early post-onset cases.

Seek evaluation from a GP or sleep specialist for: excessive daytime sleepiness that is significantly impairing daily function — particularly sleep attacks during driving, work, or meals; sudden episodes of muscle weakness or paralysis triggered by laughter or emotion (possible cataplexy — highly characteristic of narcolepsy); frequent frightening hallucinations at sleep onset or on waking; regular sleep paralysis (particularly with associated hallucinations and EDS); or a combination of several of these symptoms occurring together. Do not attribute these symptoms to laziness, depression, or shift work without investigation — narcolepsy is consistently missed for an average of 8-10 years after symptoms begin, causing enormous unnecessary impairment to education, career, and relationships. If you drive and experience excessive sleepiness, seek medical advice urgently — drowsy driving in undiagnosed narcolepsy is a significant road safety risk. Referral to a specialist sleep centre for overnight polysomnography and MSLT is required for definitive diagnosis.